Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Classement en actions #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Prix de l'action
$2.17
Capitalisation boursière
$249.58M
Changement (1 jour)
-1.67%
Changement (1 an)
96.34%
Pays
CA
Échange Cardiol Therapeutics Inc. (CRDL)

Catégorie

Ratio P/S pour Cardiol Therapeutics Inc. (CRDL)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Cardiol Therapeutics Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Cardiol Therapeutics Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes